Revised IPI (R-IPI) for DLBCL

Revised IPI (R-IPI) for DLBCL - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.

Open the Revised IPI (R-IPI) for DLBCL → Runs in your browser. No signup, no tracking.

What this is

Revised IPI (R-IPI) for DLBCL is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. Revised IPI (R-IPI) for DLBCL - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.

When to use it

Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.

References

Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. Read the source ↗

Worked example: R-IPI 3 of 5 factors -- Poor risk group; 4-year PFS ~53%, OS ~55%. Counted: age > 60, LDH above normal, stage III-IV.

Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.

Built by Clay Good. Source on GitHub.